Table 4.

Top 10 co-cited references involved in the research of PCa immunotherapy.

Title	First author	Year	Citations	Journals	IF (2020)
Sipuleucel-T immunotherapy for castration-resistant prostate cancer	Philip W Kantoff	2010	791	New England Journal of Medicine	91.245
Improved survival with ipilimumab in patients with metastatic melanoma.	F. Stephen Hodi	2010	408	New England Journal of Medicine	91.245
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial	Eugene D. Kwon	2014	385	Lancet Oncology	41.32
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer	Philip W Kantoff	2010	367	Journal of Clinical Oncology	44.54
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer	Ian F Tannock	2004	347	New England Journal of Medicine	91.245
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer	Eric J. Small	2006	344	Journal of Clinical Oncology	44.54
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer	Suzanne L. Topalian	2012	335	New England Journal of Medicine	91.245
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells	Eric J. Small	2000	274	Journal of Clinical Oncology	44.54
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer	Celestia S Higano	2009	257	Cancer	6.860
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial	Johann Sebastian de Bono	2010	251	Lancet	79.32